130 related articles for article (PubMed ID: 21512428)
1. Luminex-based desensitization protocols: the University of Wisconsin initial experience.
Niederhaus SV; Muth B; Lorentzen DF; Wai P; Pirsch JD; Samaniego-Picota M; Leverson GE; D'alessandro AM; Sollinger HW; Djamali A
Transplantation; 2011 Jul; 92(1):12-7. PubMed ID: 21512428
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
4. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy.
Chung BH; Choi BS; Oh EJ; Park CW; Kim JI; Moon IS; Kim YS; Yang CW
Transpl Int; 2014 Jan; 27(1):49-59. PubMed ID: 24118413
[TBL] [Abstract][Full Text] [Related]
6. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S
Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361
[TBL] [Abstract][Full Text] [Related]
8. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
9. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
[TBL] [Abstract][Full Text] [Related]
10. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
11. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.
Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C
Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362
[TBL] [Abstract][Full Text] [Related]
12. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients.
Mujtaba MA; Goggins W; Lobashevsky A; Sharfuddin AA; Yaqub MS; Mishler DP; Brahmi Z; Higgins N; Milgrom MM; Diez A; Taber T
Clin Transplant; 2011; 25(1):E96-102. PubMed ID: 20977497
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
14. Double-Filtration Plasmapheresis Plus Low-Dose Anti-thymocyte Globulin and Tacrolimus in Asian Living-Donor Kidney Transplantation With Donor-Specific Anti-HLA Antibody.
Kantachuvesiri S; Ingsathit A; Thammanichanond D; Choochaeam K; Sra-Ium S; Kitiyakara C; Nongnuch A; Sakulchairungrueng B; Worawichawong S
Transplant Proc; 2021 Apr; 53(3):995-1000. PubMed ID: 32948312
[TBL] [Abstract][Full Text] [Related]
15. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
16. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies.
Akalin E; Dinavahi R; Friedlander R; Ames S; de Boccardo G; Sehgal V; Schröppel B; Bhaskaran M; Lerner S; Fotino M; Murphy B; Bromberg JS
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1160-7. PubMed ID: 18337549
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a negative conversion trial and subsequent living donor kidney transplant outcome in recipients with a positive lymphocyte crossmatch.
Huh KH; Kim SI; Joo DJ; Ju MK; Chang HK; Kim HJ; Kim YS; Kim MS
Nephron Clin Pract; 2009; 111(1):c49-54. PubMed ID: 19052470
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of living donor renal transplants with a negative cross-match and pretransplant donor-specific antibody.
Knight RJ; Devos JM; Patel SJ; Land G; Moore LW; Gaber L; Gaber AO
Transplant Proc; 2013 May; 45(4):1399-401. PubMed ID: 23726582
[TBL] [Abstract][Full Text] [Related]
19. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy.
Morath C; Beimler J; Opelz G; Scherer S; Schmidt J; Macher-Goeppinger S; Klein K; Sommerer C; Schwenger V; Zeier M; Süsal C
Transpl Int; 2012 May; 25(5):506-17. PubMed ID: 22372718
[TBL] [Abstract][Full Text] [Related]
20. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
